Several other equities research analysts have also commented on the stock. ValuEngine raised shares of Vistra Energy from a hold rating to a buy rating in a report on Wednesday, July 3rd. Robert W. Baird reaffirmed an outperform rating and issued a $25.00 price target (up from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. BidaskClub raised shares of Zumiez from a sell rating to a hold rating in a report on Saturday, June 22nd. Finally, HC Wainwright reaffirmed a buy rating and issued a $48.00 price target (down from $52.00) on shares of CELYAD SA/ADR in a report on Friday, July 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $17.41.
NASDAQ:KPTI opened at $7.61 on Monday. Karyopharm Therapeutics has a one year low of $3.92 and a one year high of $21.71. The company has a debt-to-equity ratio of 0.98, a quick ratio of 6.19 and a current ratio of 6.19. The stock has a market capitalization of $463.18 million, a price-to-earnings ratio of -2.42 and a beta of 2.44. The firm has a fifty day simple moving average of $6.33.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.75 million. On average, research analysts predict that Karyopharm Therapeutics will post -3.8 EPS for the current year.
Several hedge funds have recently bought and sold shares of KPTI. Rhumbline Advisers boosted its stake in Karyopharm Therapeutics by 119.9% in the fourth quarter. Rhumbline Advisers now owns 93,819 shares of the company’s stock valued at $879,000 after buying an additional 51,163 shares in the last quarter. Prudential Financial Inc. boosted its stake in Karyopharm Therapeutics by 233.9% in the fourth quarter. Prudential Financial Inc. now owns 73,530 shares of the company’s stock valued at $689,000 after buying an additional 51,510 shares in the last quarter. First Trust Advisors LP acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at about $1,576,000. PNC Financial Services Group Inc. boosted its stake in Karyopharm Therapeutics by 660.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after buying an additional 3,300 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in Karyopharm Therapeutics by 391.0% in the fourth quarter. California Public Employees Retirement System now owns 165,746 shares of the company’s stock valued at $1,553,000 after buying an additional 131,986 shares in the last quarter. 84.20% of the stock is currently owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Recommended Story: What is a put option?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.